Meliodays Medical Secures Over EUR 800,000 in Pre-Seed Financing

Meliodays Medical GmbH has successfully closed a pre-seed financing round, raising over EUR 800,000. The round, led by capacura GmbH and supported by FS Life Science Investment GmbH along with various early-stage investors, highlights the ever-growing recognition of menstrual pain as a significant health concern worldwide.

With about 80% of menstruating individuals experiencing pain, current treatments often involve hormone therapies or high-dose painkillers with unwanted side effects. Meliodays Medical aims to address this by developing MelioOne, an innovative hormone-free treatment applied locally to alleviate menstrual pain effectively while minimizing systemic side effects.

The investment will support the progression of MelioOne's development. The company has already secured patent rights for this novel solution in over 150 countries, aiming to improve the quality of life for those affected by menstrual pain.